Trv Gp Iv LLC Takes Position in Maze Therapeutics, Inc. $MAZE

Trv Gp Iv LLC acquired a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,473,958 shares of the company’s stock, valued at approximately $133,502,907,000. Maze Therapeutics comprises about 52.6% of Trv Gp Iv LLC’s investment portfolio, making the stock its biggest position. Trv Gp Iv LLC owned approximately 0.08% of Maze Therapeutics at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of MAZE. BlackRock Inc. bought a new stake in shares of Maze Therapeutics in the 2nd quarter valued at about $104,525,000. Deutsche Bank AG bought a new stake in Maze Therapeutics in the second quarter valued at approximately $1,044,000. Alphabet Inc. bought a new stake in Maze Therapeutics in the second quarter valued at approximately $41,435,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics during the 2nd quarter valued at approximately $48,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Maze Therapeutics during the 2nd quarter valued at approximately $200,000.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MAZE shares. BTIG Research restated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Trading Up 4.2%

NASDAQ MAZE opened at $29.13 on Wednesday. The stock has a market capitalization of $1.62 billion, a P/E ratio of -11.56 and a beta of 2.22. The business has a 50 day simple moving average of $27.98 and a 200 day simple moving average of $32.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics, Inc. has a one year low of $12.81 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Research analysts expect that Maze Therapeutics, Inc. will post -2.71 earnings per share for the current year.

Insider Activity

In related news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at $717,675. This represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the sale, the chief executive officer owned 23,337 shares of the company’s stock, valued at $699,643.26. The trade was a 59.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 140,674 shares of company stock worth $3,904,707 in the last quarter. 5.30% of the stock is owned by corporate insiders.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.